CureVac(CVAC) - 2023 Q4 - Earnings Call Presentation

✓Recommendation for 100 µg as preferred dose in subsequent Phase 1 doseconfirmation Part B Fourth Quarter and Full-Year 2023 Financial Results and Business Update April 24, 2024 CureVac Speakers Alexander Zehnder Business Update Chief Executive Officer Myriam Mendila Program Update Chief Development Officer Pierre Kemula Financial Update Chief Financial Officer Marcus Dalton Q&A Session Head of Intellectual Property CureVac N.V. │ Fourth Quarter and Full-Year 2023 Results 2 Forward-Looking Statements The in ...